Supernus Provides Regulatory Update for SPN-812

ROCKVILLE, Md., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news